Toddler is in remission from stage four cancer at just 21 months old

Molly Hughes was diagnosed with neuroblastoma just before she was five months old. Fifteen months and five rounds of surgery later, the Kentucky toddler is cancer-free at last.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 17 October 2019Source: Cancer CellAuthor(s): Zulekha A. Qadeer, David Valle-Garcia, Dan Hasson, Zhen Sun, April Cook, Christie Nguyen, Aroa Soriano, Anqi Ma, Lyra M. Griffiths, Maged Zeineldin, Dan Filipescu, Luz Jubierre, Asif Chowdhury, Orla Deevy, Xiang Chen, David B. Finkelstein, Armita Bahrami, Elizabeth Stewart, Sara Federico, Soledad GallegoSummaryATRX alterations occur at high frequency in neuroblastoma of adolescents and young adults. Particularly intriguing are the large N-terminal deletions of ATRX (Alpha Thalassemia/Mental Retardation, X-linked) that generate in-frame fusion (...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Pediatric cancers represent a wide variety of different tumors, though they have unique features that distinguish them from adult cancers. Receptor tyrosine kinases KIT and TrkA functions in AML and NB, respectively, are well-characterized. Though expression of these receptors is found in both tumors, little is known about KIT function in NB and TrkA in AML. By combining gene enrichment analysis with multidimensional scaling we showed that pediatric AMLs with t(8;21) or inv16 and high KIT expression levels stand out from other AML subtypes as they share prominent transcriptomic features exclusively with KIT-overexpressing ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Kim KW, Kim JY, Qiao J, Clark RA, Powers CM, Correa H, Chung DH Abstract Neuroblastoma remains one of the most difficult pediatric solid tumors to treat. In particular, the refractory and relapsing neuroblastomas are highly heterogeneous with diverse molecular profiles. We previously demonstrated that AKT2 plays critical roles in the regulation of neuroblastoma tumorigenesis. Here we hypothesize that targeting AKT2 could block the signal transduction pathways enhanced in chemo- and/or radiation-resistant neuroblastoma cancer stem-like cells. We found cell proliferation and survival signaling pathways AKT2/...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: 14 October 2019Source: Cancer Cell, Volume 36, Issue 4Author(s): Esther R. Berko, Yael P. MosséMechanisms of acquired resistance to ALK inhibition therapy in neuroblastoma have not yet been elucidated. In a recent issue of Nature, Debruyne et al. demonstrate that resistant MYCN-amplified ALK-mutated neuroblastoma cells overexpress BORIS, resulting in wide-ranging changes in chromatin interaction and transcriptional reprogramming.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Abstract PURPOSE: Immunotherapy promises unprecedented benefits to cancer patients. However, the majority of cancer types, including high-risk neuroblastoma remain immunologically unresponsive. High intensity focused ultrasound (HIFU) is a non-invasive technique that can mechanically fractionate tumors, transforming immunologically 'cold' tumors into responsive 'hot' tumors. EXPERIMENTAL DESIGN: We treated
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Ye Xu Successful cancer therapy requires drugs being precisely delivered to tumors. Nanosized drugs have attracted considerable recent attention, but their toxicity and high immunogenicity are important obstacles hampering their clinical translation. Here we report a novel “cocktail therapy” strategy based on excess natural killer cell-derived exosomes (NKEXOs) in combination with their biomimetic core–shell nanoparticles (NNs) for tumor-targeted therapy. The NNs were self- assembled with a dendrimer core loading therapeutic miRNA and a hydrophilic NKEXOs shell. Their successful fab...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
British Journal of Cancer, Published online: 11 October 2019; doi:10.1038/s41416-019-0594-3Monozygotic twins with neuroblastoma MS have a similar molecular profile: a case of twin-to-twin metastasis
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
THURSDAY, Oct. 10, 2019 -- Early treatment with an immune-boosting therapy might improve the outlook of young children with an advanced form of cancer, a new small study suggests. The trial involved 43 children with high-risk neuroblastoma, a...
Source: - Daily MedNews - Category: General Medicine Source Type: news
CONCLUSIONS: Adding hu14.18K322A to induction chemotherapy produced early PR or better in most patients, reduced tumor volumes, improved CSs at the end of induction, and yielded an encouraging 2-year EFS. These results, if validated in a larger study, may change the standard of care for children with high-risk neuroblastoma. PMID: 31601569 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusion: Neuroblastoma survivors represent a population with a high risk of developing neurologic disorders. Our results should contribute to improving health care planning and underscores the need for systematic follow-up care of this vulnerable group of survivors. PMID: 31591921 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Health | Neuroblastoma | Neurology | Neurosurgery